XENO BIOSCIENCES
Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery. It was founded in 2015 and is headquartered in Somerville, Massachusetts.
XENO BIOSCIENCES
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2015-01-01
Address:
Somerville, Massachusetts, United States
Country:
United States
Website Url:
http://www.xenobiosciences.com
Total Employee:
1+
Status:
Active
Contact:
714-715-0970
Total Funding:
7.25 M USD
Technology used in webpage:
Viewport Meta SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Global Site Tag Google Apps For Business Typekit
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
CR Ventures
CR Ventures investment in Series A - Xeno Biosciences
Maine Angels
Maine Angels investment in Series A - Xeno Biosciences
Beacon Angels
Beacon Angels investment in Series A - Xeno Biosciences
Boston Harbor Angels
Boston Harbor Angels investment in Series A - Xeno Biosciences
Sidecar Angels
Sidecar Angels investment in Series A - Xeno Biosciences
Dirigo Angels
Dirigo Angels investment in Series A - Xeno Biosciences
Rose Ventures
Rose Ventures investment in Series A - Xeno Biosciences
Keiretsu Forum
Keiretsu Forum investment in Series A - Xeno Biosciences
Bangor Angels
Bangor Angels investment in Series A - Xeno Biosciences
Zhi Gao Holding
Zhi Gao Holding investment in Series A - Xeno Biosciences
Official Site Inspections
http://www.xenobiosciences.com Semrush global rank: 6 M Semrush visits lastest month: 1.36 K
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Xeno Biosciences"
Team — Xeno Biosciences
Board of Directors Jeffrey Arnold - Chairman, Advisor and Board Member. Mr. Arnold is the president of Arnold Strategies, LLC, a strategic advisor to early stage CEO’s, an angel investor with Boston Harbor Angels, Mass Medical …See details»
Xeno Biosciences - Crunchbase Company Profile & Funding
Xeno Biosciences is a biotechnology company that provides novel class of treatments for metabolic diseases.See details»
Xeno Biosciences Company Profile | Management and Employees …
Xenobiosciences. Primary Industries. Business Services Research & Development. Contact Information. Headquarters. 411a Highland Ave 341, Somerville, Massachusetts, 02144, United …See details»
Xeno Biosciences, Inc. - Drug pipelines, Patents, Clinical trials
Explore Xeno Biosciences, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 2 news, and 1 literature, Disease Domain ...See details»
Xeno Biosciences Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Xeno Biosciences Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
XENO BIOSCIENCES INC. - VentureRadar
Website: https://www.xenobiosciences.com. Develops innovative treatments targeting human gut microbiome, addressing unmet needs in metabolic diseases through pioneering therapeutic …See details»
XENO BIOSCIENCES INC. - VentureRadar
Website: https://www.xenobiosciences.com Xeno is a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead …See details»
Xeno Biosciences - LinkedIn
Xeno Biosciences | 214 followers on LinkedIn. Gastric Bypass in a Pill | Xeno Biosciences is a biotechnology company pioneering a novel class of treatments for metabolic diseasesSee details»
Xeno Biosciences Announces New CEO and Financing - Yahoo …
CAMBRIDGE, Mass., April 17, 2024--Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic …See details»
Science — Xeno Biosciences
Supporting air hypothesis, in healthy subjects, it is observed that gas mixtures with partial pressures (N2 & O2) equivalent to venous blood gas tensions transit rapidly to colon with minimal absorption after jejunal infusion (Dainese …See details»
XENO BIOSCIENCES INC. - VentureRadar
Similar Companies: YSOPIA Bioscience (previously LNC Therapeutics) France n/a YSOPIA Bioscience is developing biotherapies based on keystone single-strain bacteria. Of the billions …See details»
Xeno Biosciences - Overview, News & Similar companies - ZoomInfo
Who is Xeno Biosciences. Xeno Biosciences Inc. is a privately held drug development company dedicated to finding safe and effective treatments for obesity and metabolic dis eases. The …See details»
Xeno Biosciences - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Xeno Biosciences. Use the PitchBook Platform to explore the full profile.See details»
Press — Xeno Biosciences
Xeno Biosciences Announces New CEO and Financing . Cambridge, MA, April 17, 2024 – Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing …See details»
Xeno Biosciences - Products, Competitors, Financials, Employees ...
Xeno Biosciences initiate phase 1b proof-of-concept study for obesity drug candidate XEN-101. Jun 27, 2024. Xeno Biosciences has initiated a Phase 1b clinical study designed to provide …See details»
Xeno Biosciences Starts Phase 1b Proof-of-Concept Study in Obesity
Jun 25, 2024 For more information about Xeno Biosciences please contact Dr. Dennis Kim at [email protected]. Release Summary. Xeno initiates Phase 1b PoC clinical trial …See details»
Xeno Biosciences Announces New CEO and Financing - BioSpace
Apr 17, 2024 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity …See details»
XEN-101 - Xeno Biosciences
XEN-101. XEN-101 is an investigational treatment for obesity to be evaluated in a Phase I clinical trial. XEN-101 is a first-in-class oral formulation, engineered to produce weight loss by …See details»
Xeno Biosciences Announces New CEO and Financing
Apr 17, 2024 Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseaSee details»
XEN-101 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 The results of the Phase 1b study are expected by the end of 2024. For more information about Xeno Biosciences please contact Dr. Dennis Kim at …See details»